닫기
검색

Scientific Advisory Board

Patricia A D’Amore
Patricia A D’AmorePhD, MBA
Pat is a professor of Ophthalmology at Harvard Medical School and Associate Chief of Basic & Translational Research at Massachusetts Eye and Ear. She is a world-renowned ocular angiogenesis expert who has made significant contributions in the identification of vascular endothelial growth factor (VEGF), a potent angiogenetic growth factor that causes pathological blood vessel growth identified in neovascular eye diseases. Her extensive research has led to the approval of anti-VEGF therapies for treating wet aged-related macular degeneration (AMD) and diabetic retinopathy (DR). She also developed the oxygen-induced retinopathy(OIR) mouse model, which is widely used for basic scientific investigations vascular development, as well as in preclinical studies of anti-angiogenic ocular therapeutics. She has published more than 160 peer-reviewed papers and is the recipient of the Alcon Research Institute Award, the Cogan Award from ARVO, the Rous-Whipple Award from the American Society of Investigative Pathology, the Endre A. Balazs Award from the International Society for Eye Research, and the Proctor Medal from ARVO
Peter Kertes
Peter KertesMD, CM, FRCSC
Peter is Chief of Ophthalmology at the Sunnybrook Health Centre and an Associate Professor in the Department of Ophthalmology at the University of Toronto. He is a retinal surgeon with extensive experience in clinical trials for anti-angiogenic agents and is in search for better treatments for wet age-related macular degeneration(AMD) and diabetic retinopathy(DR). He specializes in the diagnosis and treatment of diseases of the retina, macula, and vitreous. With a burgeoning interest in international ophthalmology and pediatric retinal diseases such as Retinopathy of Prematurity(ROP), Peter seeks for opportunities volunteering his expertise.

Se joon Woo
Se joon WooMD, PhD

Sejoon is an Associate Professor of Ophthalmology at Seoul National University Bundang Hospital(SNUBH). He is an active scientific researcher and ophthalmology medical doctor specializing in Pharmacokinetics(PK) study which is increasingly important for the successful development of anti-angiogenic therapies. He is also involved in multiple global clinical trials of novel retinal treatments and biosimilar agents, and has recently led the phase 3 global clinical trials of Lucentis biosimilar developed by Samsung Bioepis. He has published more than 230 peer-reviewed papers. 

Judy E. Kim
Judy E. KimMD

Judy is a professor of Ophthalmology at Medical college of Wisconsin and an experienced expert in clinical trials of anti-angiogenic agents. With specialties in treating diabetic retinopathy(DR) and diabetic macular edema(DME), she serves as the Vice Chairman of DRCR(Diabetic Retinopathy Clinical Research) Retina Network, a National Eye Institute(NEI)-funded professional network with more than 500 physicians from the US and Canada, pursuing to improve vision and quality of life for people of retinal diseases by conducting multicenter clinical research focused on retinal disorders. 

Robert S. Kerbel
Robert S. KerbelPhD

Bob is a senior scientist at Sunnybrook Health Centre located in Toronto and a professor at the University of Toronto. Neither an ophthalmologist nor an ocular specialist, he is a global scholar in the field of angiogenesis--a key pathologic mechanism of retinal diseases. His scientific interest mostly lies in improving clinical translation and overcoming anti-angiogenic drug resistance. He has published around 420 papers with a total of 45,000 cited cases.